Zacks Investment Research downgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning.
According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
A number of other brokerages also recently weighed in on ENTA. BidaskClub upgraded shares of Enanta Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, June 22nd. JMP Securities reiterated a buy rating and issued a $120.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, July 31st. UBS Group downgraded shares of Enanta Pharmaceuticals from an outperform rating to a market perform rating in a research report on Wednesday, August 8th. Finally, Oppenheimer set a $100.00 price target on shares of Enanta Pharmaceuticals and gave the company a hold rating in a research report on Tuesday, August 14th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Enanta Pharmaceuticals presently has a consensus rating of Hold and an average price target of $104.00.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported $0.97 earnings per share for the quarter, missing analysts’ consensus estimates of $0.98 by ($0.01). The firm had revenue of $57.26 million during the quarter, compared to analyst estimates of $56.59 million. Enanta Pharmaceuticals had a net margin of 37.63% and a return on equity of 25.84%. Equities research analysts anticipate that Enanta Pharmaceuticals will post 3.56 earnings per share for the current year.
In related news, insider Tim Ocain sold 25,000 shares of the stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $83.64, for a total value of $2,091,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Nathalie Adda sold 4,155 shares of the stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $95.32, for a total transaction of $396,054.60. Following the completion of the sale, the vice president now owns 4,155 shares in the company, valued at $396,054.60. The disclosure for this sale can be found here. Insiders sold a total of 33,310 shares of company stock worth $2,870,644 over the last quarter. 10.56% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of ENTA. SG Americas Securities LLC bought a new stake in Enanta Pharmaceuticals during the 1st quarter worth approximately $112,000. Sei Investments Co. increased its stake in Enanta Pharmaceuticals by 63,966.7% during the 1st quarter. Sei Investments Co. now owns 1,922 shares of the biotechnology company’s stock worth $156,000 after purchasing an additional 1,919 shares in the last quarter. Zeke Capital Advisors LLC bought a new stake in Enanta Pharmaceuticals during the 2nd quarter worth approximately $216,000. Meeder Asset Management Inc. increased its stake in Enanta Pharmaceuticals by 123.4% during the 2nd quarter. Meeder Asset Management Inc. now owns 2,317 shares of the biotechnology company’s stock worth $269,000 after purchasing an additional 1,280 shares in the last quarter. Finally, A.R.T. Advisors LLC bought a new stake in Enanta Pharmaceuticals during the 1st quarter worth approximately $278,000. 77.68% of the stock is owned by institutional investors and hedge funds.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Read More: Stock Split
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.